| scholarly article | Q13442814 |
| P2093 | author name string | J R Martin | |
| H Möhler | |||
| U Rudolph | |||
| F Crestani | |||
| P2860 | cites work | Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. | Q33902217 |
| Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. | Q33902225 | ||
| Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects | Q34558742 | ||
| Pharmacological and behavioral profile of alpidem as an anxiolytic | Q35001844 | ||
| Novel anxiolytics that act as partial agonists at benzodiazepine receptors | Q37607589 | ||
| A synthetic non-benzodiazepine ligand for benzodiazepine receptors: A probe for investigating neuronal substrates of anxiety | Q39277947 | ||
| Abecarnil: a novel anxiolytic with mixed full agonist/partial agonist properties in animal models of anxiety and sedation. | Q40622011 | ||
| Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats | Q48459196 | ||
| Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. | Q51434685 | ||
| Management of insomnia | Q73020933 | ||
| GABAA receptor subtypes differentiated by their gamma-subunit variants: prevalence, pharmacology and subunit architecture | Q73026243 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1251-1254 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Mechanism of action of the hypnotic zolpidem in vivo | |
| P478 | volume | 131 |
| Q28180798 | 5,7-Dihydroxy-6-methoxyflavone, a benzodiazepine site ligand isolated from Scutellaria baicalensis Georgi, with selective antagonistic properties |
| Q34447083 | A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test |
| Q37979871 | A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia |
| Q53405576 | Altered ultradian cortisol rhythmicity as a potential neurobiologic substrate for chronic insomnia. |
| Q30495530 | Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice |
| Q40894855 | An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists |
| Q46834558 | Anticonvulsant and anxiolytic-like effects of compounds isolated from Polygala sabulosa (Polygalaceae) in rodents: in vitro and in vivo interactions with benzodiazepine binding sites. |
| Q43261573 | Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors |
| Q40927742 | Anxiolytic activity of pyridoindole derivatives SMe1EC2 and SMe1M2: behavioral analysis using rat model |
| Q30466591 | Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes |
| Q37490399 | Bottom-Up versus Top-Down Induction of Sleep by Zolpidem Acting on Histaminergic and Neocortex Neurons. |
| Q44136555 | Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes |
| Q40434728 | Context Dependent Benzodiazepine Modulation of GABAA Receptor Opening Frequency |
| Q40699578 | Contribution of the alpha1-GABA(A) receptor subtype to the pharmacological actions of benzodiazepine site inverse agonists |
| Q28551945 | Coupling of Thalamocortical Sleep Oscillations Are Important for Memory Consolidation in Humans |
| Q48024772 | Dependence, misuse, and beliefs regarding use of hypnotics by elderly psychiatric patients taking zolpidem, estazolam, or flunitrazepam |
| Q94502481 | Dieckol, a Major Marine Polyphenol, Enhances Non-Rapid Eye Movement Sleep in Mice via the GABAA-Benzodiazepine Receptor |
| Q44678938 | Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei |
| Q34580275 | Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. |
| Q42482334 | Differential localization of GABA(A) receptor subunits in relation to rat striatopallidal and pallidopallidal synapses. |
| Q36234280 | Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward |
| Q46761500 | Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats |
| Q42567743 | Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress |
| Q24675330 | Diverse mechanisms of antiepileptic drugs in the development pipeline |
| Q37939671 | Drug-induced sleep: theoretical and practical considerations |
| Q30374041 | Early postnatal GABAA receptor modulation reverses deficits in neuronal maturation in a conditional neurodevelopmental mouse model of DISC1. |
| Q44931603 | Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task |
| Q37177059 | Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time |
| Q33328007 | Emerging approaches for the syntheses of bicyclic imidazo[1,2-x]-heterocycles |
| Q27303584 | Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target |
| Q24656199 | Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization |
| Q36166392 | From synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors. |
| Q47675999 | GABA Receptors and the Pharmacology of Sleep. |
| Q37115526 | GABA effects during neuronal differentiation of stem cells. |
| Q44170008 | GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. |
| Q36799974 | GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders |
| Q34204921 | GABA(A) receptor subtypes: dissecting their pharmacological functions |
| Q35152245 | GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? |
| Q48483060 | GABAA receptor subtype specific enhancement of inhibition in human motor cortex |
| Q44675359 | GABAA/alpha1 receptor agonists and antagonists: effects on species-typical and heightened aggressive behavior after alcohol self-administration in mice |
| Q36675876 | Genetic variability in glutamic acid decarboxylase genes: associations with post-traumatic seizures after severe TBI. |
| Q51076268 | High-throughput screening of clinically approved drugs that prime polyethylenimine transfection reveals modulation of mitochondria dysfunction response improves gene transfer efficiencies. |
| Q90288188 | Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety |
| Q38753423 | Identification of small molecules that improve ATP synthesis defects conferred by Leber's hereditary optic neuropathy mutations |
| Q34573086 | Imidazenil and diazepam increase locomotor activity in mice exposed to protracted social isolation. |
| Q37012643 | Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem |
| Q42839020 | Impairment of locomotor activity induced by the novel N-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice |
| Q39064328 | Instructing Perisomatic Inhibition by Direct Lineage Reprogramming of Neocortical Projection Neurons |
| Q44448516 | Intrinsic and synaptic dynamics interact to generate emergent patterns of rhythmic bursting in thalamocortical neurons. |
| Q39493049 | Involvement of ATP-sensitive potassium channels and the opioid system in the anticonvulsive effect of zolpidem in mice |
| Q37156667 | Isoflurane modulates excitability in the mouse thalamus via GABA-dependent and GABA-independent mechanisms. |
| Q37698992 | Little evidence of a role for the α1GABAA subunit-containing receptor in a rhesus monkey model of alcohol drinking |
| Q46532940 | Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists |
| Q48710361 | Making sense of GABA(A) receptor subtypes: is a new nomenclature needed? |
| Q34572122 | Mice lacking Gad2 show altered behavioral effects of ethanol, flurazepam and gabaxadol. |
| Q41857666 | Molecular and functional diversity of GABA-A receptors in the enteric nervous system of the mouse colon |
| Q28681145 | Molecular mechanisms of antiseizure drug activity at GABAA receptors |
| Q34563017 | Neuroactive steroid mechanisms and GABA type A receptor subunit assembly in hypothalamic and extrahypothalamic regions |
| Q48151839 | Neurobiological correlates of state-dependent context fear |
| Q92340030 | Neuropharmacological potential of various morphological parts of Camellia sinensis L |
| Q35580605 | Neurosteroids, GABAA receptors, and escalated aggressive behavior |
| Q90636795 | Optical probing of orexin/hypocretin receptor antagonists |
| Q37323385 | Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis |
| Q38579331 | Pathophysiological aspects of diversity in neuronal inhibition: a new benzodiazepine pharmacology |
| Q36020907 | Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships |
| Q34725259 | Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects. |
| Q22305839 | Postural Instability and Consequent Falls and Hip Fractures Associated with Use of Hypnotics in the Elderly |
| Q53714273 | Potential functional and pathological side effects related to off-target pharmacological activity. |
| Q27324760 | Rapid assessment of sleep-wake behavior in mice |
| Q35187772 | Reducing GABA receptors |
| Q35069575 | SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. |
| Q37639811 | Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics |
| Q44588647 | Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. |
| Q46793491 | Sedative and anticonvulsant effects of zolpidem in adult and aged mice. |
| Q89920628 | Selected Pharmaceuticals in Different Aquatic Compartments: Part I-Source, Fate and Occurrence |
| Q35993512 | Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs |
| Q44085189 | Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. |
| Q34982306 | Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders |
| Q36686927 | Structure, pharmacology, and function of GABAA receptor subtypes. |
| Q30483976 | Studying Cerebellar Circuits by Remote Control of Selected Neuronal Types with GABA(A) Receptors |
| Q59242573 | Synthesis and Pharmacological Evaluation of Novel GABAA Subtype Receptor Ligands with Potential Anxiolytic-like and Anti-hyperalgesic Effect |
| Q38190472 | The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors |
| Q41846599 | The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice |
| Q28818208 | The effect of Zataria multiflora Boiss hydroalcoholic extract and fractions in pentylenetetrazole-induced kindling in mice |
| Q48128828 | The effect of non-benzodiazepine hypnotics on sleep quality and severity in patients with OSA: a meta-analysis |
| Q89333695 | The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels |
| Q39676883 | The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells. |
| Q35202929 | The neurobiology and control of anxious states |
| Q28267900 | The neurobiology of antiepileptic drugs |
| Q36948429 | The non-benzodiazepine hypnotic zolpidem impairs sleep-dependent cortical plasticity. |
| Q35854608 | The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents |
| Q59652783 | UHPLC-MS/MS and UHPLC-HRMS identification of zolpidem and zopiclone main urinary metabolites and method development for their toxicological determination |
| Q35631836 | Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder |
| Q55057714 | Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects. |
| Q61449922 | Zolpidem Activation of Alpha 1-Containing GABA Receptors Selectively Inhibits High Frequency Action Potential Firing of Cortical Neurons |
| Q37994346 | Zolpidem for insomnia |
| Q46816718 | Zolpidem in a minimally conscious state |
| Q35583074 | Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series |
| Q33811924 | Zolpidem modulation of phasic and tonic GABA currents in the rat dorsal motor nucleus of the vagus |
| Q27331440 | Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope |
| Q37666650 | Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation |
| Q30368912 | α2-containing GABA(A) receptors: a requirement for midazolam-escalated aggression and social approach in mice |
| Q34295813 | α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. |
| Q44658144 | α2‐γ‐Aminobutyric acid (GABA)A receptors are the molecular substrates mediating precipitation of narcosis but not of sedation by the combined use of diazepam and alcohol in vivo |
Search more.